Navigation Links
Mindray Medical Announces Preliminary 2010 Operating Results
Date:1/10/2011

11 revenue growth target for the overall organization of at least 16%. Over the coming year we will look to grow profits and market share by driving new market segment penetration with products launched over the last two years, increasing efficiency of R&D, focusing on R&D investment to recruit engineering talent and broaden our product pipeline, expanding our presence in important emerging markets, further building up our developed market sales capabilities, leveraging our domestic leadership and progressing with our initiatives in sales force re-alignment, product development, branding and marketing in China.  We will also strive to improve the effectiveness of our working capital utilization and adjust our overall strategy as necessary to better compete globally."

Mindray's preliminary 2010 results are unaudited and remain subject to the finalization of the company's year-end closing, reporting and audit processes. 2011 full-year guidance will be provided in the fourth quarter and 2010 year-end earnings announcement.

About MindrayWe are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we are able to supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://ir.mindray.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. Mindray Medical Announces Shareholder Resolutions Adopted at 2010 Annual General Meeting
3. Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010
4. Mindray Announces Third Quarter 2010 Financial Results
5. Mindray Medical Announces Participation in Upcoming Investor Conferences
6. Mindray to Report Third Quarter 2010 Financial Results on November 8, 2010
7. Mindray Medical to Exhibit New Products at 64th China International Medical Equipment Fair
8. Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer
9. /C O R R E C T I O N - Mindray Medical International Limited /
10. Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference
11. Mindray Medical to Present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Fruit Street Health ... initial seed round of funding. The ... by a series of individual investors, the majority of ... in the initial round are; Houston Cardiology Consultants ... Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
(Date:9/18/2014)... 2014  KIYATEC announced today that it has ... Research (SBIR) Phase II Contract from the National ... and centers that comprise the National Institutes of ... year award, KIYATEC will expand its 3D breast ... forefront of cancer therapy strategies: 1) cancer,s interaction ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... endothelial growth factor (VEGF) agent for wet AMD, is ... Advantage plans as Genentech,s Lucentis, which is the standard ... managed care organization (MCO) directors do not identify a ... slightly more likely than Lucentis to be listed on ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
... 31, 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd ... clinical study to confirm the efficacy of its novel ... trial is evaluating the efficacy, safety and tolerability of ... compared to vehicle. The trial consists of treating 132 ...
... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... BSTC ), a biopharmaceutical company, today announced ... Companies and announced plans to move XIAFLEX forward in ... as well as to collaborate on the initiation of ...
Cached Medicine Technology:Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 2Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 2Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 4Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 5Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 6Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 7Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 8
(Date:9/18/2014)... 18, 2014 It is that time of ... and wellness. Once again, Evensong Spa at ... offering three services at a special $50 rate Oct. 20 ... Marcus Hotels & Resorts , is the only Wisconsin ... Americans to embrace health and wellness by experiencing affordable spa ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, ... common antidepressant can quickly alter the way brain cells communicate ... online Sept. 18 in Current Biology , are ... prescribed antidepressants. Experts said the hope is to eventually be ... benefit from a drug -- and which people would fare ...
(Date:9/18/2014)... is good for you. But new research from University ... added benefit for cancer patients undergoing chemotherapy. , Their ... that combining exercise with chemotherapy shrunk tumors more than ... in the School of Nursing and director of the ... senior author on the study, which appears in the ...
(Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
(Date:9/18/2014)... 2014 Thousands of college and high ... shared fundraising impact on 127 member Children’s Miracle ... first-ever Dance Marathon Day will officially kick off a ... be raised by college and high school students funding ... through Dance Marathon campus programs help provide medical equipment, ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2
... Multiple approaches are found to boost success of people ... -- To truly help people quit smoking, doctors need ... might require repeated or intensive interventions, including pharmacotherapy and ... 750 people who smoked at least 10 cigarettes a ...
... April 8 Dialysis Corporation of America (Nasdaq: ... into a grant agreement with the University of ... $265,000 each year, for the next three years, will ... clinical research relating to kidney disease. This multi-year agreement ...
... much less nausea while receiving radiation treatment, making the ... to a study published in the Journal of ... Medical Center researchers. , Previous research has suggested ... to your body that you expect to happen ...
... Individuals How Much They Will Pay for Treatment ... Their HealthcareANN ARBOR, Mich., April 8 As ... its cost, employers and health insurers need better ... well-informed decisions about their health and use of ...
... community of hope. PHILADELPHIA, April 8 Kyle,s Treehouse ... announces their new initiative for Autism Awareness Month: Autism151, ... Autism151 focuses on the positive side of the autism ... stories of strength, inspiration and success with one another, giving ...
... State Tobacco Prevention ProgramsCOLUMBUS, Ohio, April 8 ... tobacco and flavored little cigars - are addictive and ... rate as cigarettes in Ohio, according to a radio ... health organizations.(Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ...
Cached Medicine News:Health News:Doctors Urged to Get Aggressive to Help Smokers 2Health News:Dialysis Corporation of America Announces Establishment of Clinical Grant Agreement with the University of Cincinnati, College of Medicine 2Health News:Wristbands ease nausea with cancer treatment 2Health News:HealthEquity, a Leading Healthcare Account Administrator, Licenses Thomson Reuters Information Solutions to Help People Make Better Healthcare Decisions 2Health News:HealthEquity, a Leading Healthcare Account Administrator, Licenses Thomson Reuters Information Solutions to Help People Make Better Healthcare Decisions 3Health News:Kyle's Treehouse Launches Autism151.com for Autism Awareness Month 2Health News:New Ohio Ad Campaign Calls for Taxing All Tobacco Products at Same Rate 2
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: